14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
PLUR vs SCNI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Scinai Immunotherapeutics Ltd. (SCNI) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas SCNI carries 47.3/100 (HOLD) at $0.38 (N/M Forward P/E, -276.1% operating margin).
Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile SCNI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLUR vs SCNI. Trailing 12-month operating profitability (PLUR -2454.5% vs SCNI -276.1%) and valuation multiples (PLUR 3.6x vs SCNI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.1M market capitalization and -276.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PLUR vs SCNI Key Questions & Quantitative Answers
As of Nov 17, 2026, Scinai Immunotherapeutics Ltd. (SCNI) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PLUR carries a Unified Composite Score of 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin), whereas SCNI carries 47.3/100 (HOLD) at $0.38 (N/M Forward P/E, -276.1% operating margin). Technical & Structure Timing Caution: PLUR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile SCNI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SCNI leads the Growth & Scale pillar: PLUR posts -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin), compared with SCNI at +572.5% YoY revenue growth and +87.2% YoY earnings growth on $3.1M TTM revenue (N/A gross margin, -276.1% operating margin). On trailing 12-month operating scale, PLUR generates $1.0M in USD-normalized revenue versus $3.1M for SCNI. In operating R&D and SG&A reinvestment, PLUR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SCNI.
SCNI screens cheaper on headline valuation multiples. PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin), whereas SCNI trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLUR (-1022.0% ROE) versus SCNI (-26.1% ROE) capital efficiency.
In options market volatility and institutional positioning, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk). By comparison, SCNI carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.85β · 82% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.